Summary
0QF Chart
Moderna Shares Jump With Positive Test Results for MRNA Flu Vaccine
The biotechnology company's messenger RNA flu vaccine candidate showed positive results in a late-stage trial.
Moderna's flu vaccine shows positive late-stage trial results, paving way for combination Covid shot
Moderna said its experimental mRNA-based flu vaccine produced a stronger immune response than a currently available shot for the virus in a late-stage trial. The positive data pave the way for Moderna to apply for approval of its standalone flu vaccine, called mRNA-1010, later this year.
Moderna Announces Positive Phase 3 Results for Seasonal Influenza Vaccine
mRNA-1010 demonstrated superior relative vaccine efficacy that was 26.6% (95% CI; 16.7%, 35.4%) higher than a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older CAMBRIDGE, MA / ACCESS Newswire / June 30, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive results from a Phase 3 efficacy study (P304) evaluating the relative vaccine efficacy (rVE) against influenza illness of mRNA-1010, the Company's seasonal influenza (flu) vaccine candidate, compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older. mRNA-1010 achieved the most stringent superiority criterion prespecified in the protocol, with an rVE of 26.6% (95% CI; 16.7%, 35.4%) in the overall study population.
Moderna Inc. Dividends
Moderna Inc. Earnings
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | 0.03 EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 1 Aug 2024 Date | | - Cons. EPS | - EPS |
| 30 Apr 2025 Date | | - Cons. EPS | - EPS |
| 20 Feb 2025 Date | | - Cons. EPS | - EPS |
| 7 Nov 2024 Date | | - Cons. EPS | 0.03 EPS |
| 31 Oct 2024 Date | | - Cons. EPS | - EPS |
| 1 Aug 2024 Date | | - Cons. EPS | - EPS |
Moderna Inc. (0QF) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Moderna Inc. ever had a stock split?
Moderna Inc. Profile
| Biotechnology Industry | Healthcare Sector | Stephane Bancel CEO | XHAN Exchange | US60770K1079 ISIN |
| US Country | 5,800 Employees | - Last Dividend | - Last Split | 7 Dec 2018 IPO Date |
Overview
Moderna, Inc., is a pioneering biotechnology firm founded in 2010, with its headquarters located in Cambridge, Massachusetts. Initially known as Moderna Therapeutics, Inc., the company rebranded to Moderna, Inc. in August 2018. It specializes in leveraging messenger RNA (mRNA) technology to develop, discover, and commercialize therapeutics and vaccines for a wide array of diseases. These diseases range from infectious diseases, immuno-oncology, rare diseases, to autoimmune and cardiovascular diseases. Moderna's operations span across the United States, Europe, and globally. The company has established strategic alliances and collaborations with notable entities in the biotech and pharmaceutical industry, including AstraZeneca, Merck & Co., Inc, Vertex Pharmaceuticals, Chiesi Farmaceutici S.p.A., and The Bill & Melinda Gates Foundation, among others.
Products and Services
- Respiratory Vaccines
Moderna's respiratory portfolio includes vaccines against COVID-19, influenza, and respiratory syncytial virus. The company utilizes its mRNA technology to develop vaccines like Spikevax, as well as its hMPV/PIV3 vaccine candidates, targeting multiple respiratory pathogens.
- Latent Vaccines
The latent vaccines developed by Moderna target a variety of viruses such as the cytomegalovirus, Epstein-Barr virus, herpes simplex virus, varicella zoster virus, and the human immunodeficiency virus. These vaccines aim to provide immunity against viruses that remain dormant in the body and can cause disease upon reactivation.
- Public Health Vaccines
Moderna's public health vaccines include projects against diseases like Zika, Nipah, and Mpox. These vaccines are part of Moderna's commitment to addressing emerging public health threats and pandemics with swift vaccine development.
- Infectious Diseases Vaccines
Vaccines against Lyme disease and norovirus fall under this category. Moderna leverages its mRNA platform to create vaccines designed to protect against widespread and challenging infectious diseases.
- Systemic Secreted and Cell Surface Therapeutics
This innovative category includes therapies that are administered systemically to target secreted and cell surface proteins, leveraging mRNA technology for treating various conditions beyond infectious diseases, including potential treatments for autoimmune and cardiovascular diseases.
- Cancer Vaccines
Moderna's oncology portfolio includes personalized cancer vaccines, KRAS vaccines, and checkpoint vaccines. These products represent an extension of mRNA technology into the field of immuno-oncology, targeting the immune system to fight cancer.
- Intratumoral Immuno-Oncology Products
These are innovative treatments administered directly into tumors to elicit a more potent and localized immune response against cancer. They form part of Moderna's broader strategy to harness the body's immune system in combating cancer.
- Rare Disease Intracellular Therapeutics
Moderna is developing therapies for rare diseases by targeting intracellular mechanisms. These therapeutics are designed to address genetic disorders and diseases with limited treatment options.
- Inhaled Pulmonary Therapeutics
The company is also exploring the potential of inhaled therapies for diseases affecting the lungs, utilizing its mRNA technology to create novel treatments for pulmonary conditions.
Contact Information
